Short Interest in BriaCell Therapeutics Corp. (NASDAQ:BCTX) Grows By 11.3%

BriaCell Therapeutics Corp. (NASDAQ:BCTX) saw a significant increase in short interest during the month of May. As of May 31st, there was short interest totalling 718,900 shares, an increase of 11.3% from the May 15th total of 645,700 shares. Currently, 4.8% of the company’s shares are sold short. Based on an average daily volume of 122,600 shares, the short-interest ratio is presently 5.9 days.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of BriaCell Therapeutics in a research report on Tuesday, June 4th.

BriaCell Therapeutics Price Performance

NASDAQ BCTX traded up $0.06 on Friday, reaching $1.42. The company had a trading volume of 63,867 shares, compared to its average volume of 220,938. The firm has a market cap of $25.96 million, a price-to-earnings ratio of -1.14 and a beta of 1.28. BriaCell Therapeutics has a fifty-two week low of $1.27 and a fifty-two week high of $7.59. The business has a 50 day moving average of $1.91 and a two-hundred day moving average of $3.21.

BriaCell Therapeutics (NASDAQ:BCTX) last issued its quarterly earnings results on Monday, March 18th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.51). As a group, research analysts predict that BriaCell Therapeutics will post -1.39 earnings per share for the current fiscal year.

Institutional Trading of BriaCell Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Onyx Bridge Wealth Group LLC lifted its position in shares of BriaCell Therapeutics by 66.7% in the 1st quarter. Onyx Bridge Wealth Group LLC now owns 50,000 shares of the company’s stock worth $143,000 after purchasing an additional 20,000 shares during the period. K.J. Harrison & Partners Inc lifted its holdings in BriaCell Therapeutics by 7.8% in the first quarter. K.J. Harrison & Partners Inc now owns 87,044 shares of the company’s stock valued at $249,000 after buying an additional 6,329 shares during the period. National Bank of Canada FI lifted its holdings in BriaCell Therapeutics by 200.0% in the fourth quarter. National Bank of Canada FI now owns 7,500 shares of the company’s stock valued at $40,000 after buying an additional 5,000 shares during the period. Finally, K2 Principal Fund L.P. bought a new stake in BriaCell Therapeutics during the third quarter valued at $156,000. Institutional investors and hedge funds own 15.42% of the company’s stock.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.